Description: <p><b>Marjoram (Origanum majorana)</b> — also known as sweet marjoram, is an aromatic Lamiaceae herb used as a culinary spice and medicinal plant. Its biologically active preparations include whole-leaf extracts, hydroalcoholic or ethanolic extracts, teas, and marjoram essential oil. It is classified as a botanical/natural-product mixture rather than a single molecular agent. Standard abbreviations used in the literature include OM, OME for Origanum majorana extract, and OMEO or OmEO for Origanum majorana essential oil. Major constituents vary substantially with cultivar, geography, extraction method, and plant part and can include terpinen-4-ol, sabinene hydrate, α-terpinene, γ-terpinene, rosmarinic acid, ursolic acid, flavonoids, and other phenolics. The extract and essential oil should not be treated as pharmacologically interchangeable because their compositions differ considerably.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of caspase-dependent apoptosis, involving p38 MAPK activation, caspase-8, caspase-9 and caspase-3/7, PARP cleavage, and suppression of survivin.</li>
<li>Suppression of NF-κB-linked tumor survival, migration, invasion, angiogenic signaling, and metastasis, with reductions in MMP-2, MMP-9, uPAR, ICAM-1 and VEGF and increased E-cadherin in breast-cancer models.</li>
<li>Modulation of autophagy and mTOR/p70S6K signaling. Essential oil induces p38-dependent protective autophagy with mTOR/p70S6K suppression and caspase-dependent p70S6K cleavage, whereas ethanolic extract can induce abortive autophagy; therefore the functional direction is formulation- and model-dependent.</li>
<li>DNA damage and cell-cycle disruption, including γ-H2AX induction, mitotic arrest, p21 elevation, histone H3/H4 hyperacetylation, and subsequent apoptosis at higher concentrations.</li>
<li>Suppression of metastatic phenotypes and tumor growth in preclinical breast- and lung-cancer models, including inhibition of migration, invasion, endothelial adhesion and tumor vascular/metastatic signaling.</li>
<li>Redox modulation is secondary/context-dependent. Marjoram preparations commonly show antioxidant and ROS-scavenging activity in non-cancer systems, but ROS elevation has not been established as a universal primary mechanism of whole-marjoram anticancer cytotoxicity.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetic data for standardized whole-marjoram extracts or OMEO are inadequate. Essential-oil monoterpenes are lipophilic and volatile and are expected to undergo rapid absorption, distribution and metabolic clearance, while phenolic extracts have a different exposure profile. Published reviews specifically identify pharmacokinetic and bioavailability characterization as a major knowledge gap. Botanical composition and extraction method are therefore major determinants of expected exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most mechanistic cancer experiments use relatively high extract or essential-oil concentrations. Examples include approximately 150–600 µg/mL ethanolic extract and approximately 64–640 µg/mL essential oil in colorectal models. Comparable systemic concentrations have not been demonstrated in humans after culinary intake, tea, or conventional supplementation. These studies should therefore be interpreted as mechanistic/preclinical evidence rather than evidence that equivalent tumor concentrations are achievable orally.</p>
<p><b>Clinical evidence status:</b> Cancer: preclinical only, with cell-culture, chick-embryo and animal tumor evidence but no established human anticancer efficacy. Alzheimer’s disease: preclinical, including Aβ1-42 rat, neuroinflammation mouse, zebrafish, AChE and oxidative-stress studies; no established human AD treatment evidence. Small randomized human studies of marjoram have been conducted for other indications including Parkinson’s disease symptoms, PCOS and stress/anxiety, demonstrating human exposure but not validating anticancer or anti-Alzheimer efficacy.</p>
<h3>Mechanistic profile in cancer</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>p38 MAPK and caspase apoptosis</td>
<td>p38 MAPK ↑; caspase-8 ↑; caspase-9 ↑; caspase-3/7 ↑; PARP cleavage ↑; survivin ↓</td>
<td>Insufficient comparable mechanistic data</td>
<td>R/G</td>
<td>Apoptotic tumor-cell death</td>
<td>One of the strongest mechanistically demonstrated axes. Pharmacologic p38 inhibition reduces OMEO-induced apoptosis in HT-29 cells.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB invasion and metastasis signaling</td>
<td>NF-κB ↓; IκB phosphorylation ↓; MMP-2 ↓; MMP-9 ↓; uPAR ↓; ICAM-1 ↓; VEGF ↓; E-cadherin ↑</td>
<td>Not adequately characterized</td>
<td>G</td>
<td>Migration, invasion and metastatic potential ↓</td>
<td>Demonstrated particularly in aggressive MDA-MB-231 breast-cancer cells and supported by chick-embryo tumor/metastasis experiments. NF-κB suppression has also been observed in HepG2 cells.</td>
</tr>
<tr>
<td>3</td>
<td>Autophagy and mTOR/p70S6K</td>
<td>Autophagy ↑; mTOR/p70S6K ↓; p70S6K cleavage ↑</td>
<td>Insufficient data</td>
<td>R/G</td>
<td>Autophagy modulation with impaired growth signaling</td>
<td>OMEO induces protective autophagy, meaning autophagy can partially protect tumor cells while apoptosis causes death. Ethanolic extract can instead produce abortive autophagy. Functional effect is formulation-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>TNF-α extrinsic apoptosis</td>
<td>TNF-α signaling ↑; caspase-8 ↑; caspase-3/7 ↑; survivin ↓</td>
<td>Not established</td>
<td>G</td>
<td>Extrinsic apoptotic signaling ↑</td>
<td>Observed in breast and colorectal models, particularly at cytotoxic extract concentrations.</td>
</tr>
<tr>
<td>5</td>
<td>DNA damage and mitotic arrest</td>
<td>γ-H2AX ↑; DNA double-strand damage ↑; mitotic arrest ↑; p21 ↑</td>
<td>Dose-dependent genotoxicity reported with concentrated methanolic extract</td>
<td>R/G</td>
<td>Cell-cycle disruption followed by death</td>
<td>Concentration is important. Lower concentrations can produce mitotic arrest without immediate apoptosis; higher concentrations trigger extensive apoptosis. Recent toxicology data indicate that genotoxicity cannot be assumed to be tumor-selective.</td>
</tr>
<tr>
<td>6</td>
<td>Survivin</td>
<td>Survivin ↓</td>
<td>Not established</td>
<td>G</td>
<td>Apoptosis resistance ↓</td>
<td>Repeated in colorectal, breast and NSCLC models and may represent a useful cross-tumor mechanistic target.</td>
</tr>
<tr>
<td>7</td>
<td>Cell adhesion and epithelial phenotype</td>
<td>E-cadherin ↑; endothelial adhesion ↓; transendothelial migration ↓</td>
<td>Not established</td>
<td>G</td>
<td>Metastatic dissemination ↓</td>
<td>Most strongly demonstrated in MDA-MB-231 breast-cancer cells.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenic signaling</td>
<td>VEGF ↓</td>
<td>Not established</td>
<td>G</td>
<td>Pro-angiogenic signaling ↓</td>
<td>Part of the broader NF-κB-linked anti-invasive phenotype; direct clinical antiangiogenic activity has not been established.</td>
</tr>
<tr>
<td>9</td>
<td>Oxidative stress and ROS</td>
<td>ROS ↑ (context-dependent); ROS ↓ reported with some essential-oil preparations</td>
<td>ROS ↓ / antioxidant effects commonly reported</td>
<td>R/G</td>
<td>Redox stress modulation</td>
<td>Aqueous O. majorana extract produced a strong dose-dependent ROS increase in MCF-7 breast cancer cells, reaching approximately 10- to 14-fold at 200–350 µg/mL. In contrast, O. majorana essential oil reduced ROS in B16F10 melanoma cells. ROS direction therefore depends strongly on extract composition, dose and cancer model.</td>
</tr>
<tr>
<td>10</td>
<td>Normal-cell selectivity</td>
<td>Cytotoxicity ↑ (dose-dependent)</td>
<td>Cytotoxicity ↔ at some tested extract concentrations; toxicity possible at higher exposures</td>
<td>G</td>
<td>Potential therapeutic selectivity</td>
<td>Some recent preparations showed greater cytotoxicity toward cancer cells than normal fibroblasts, but composition varies and this does not establish a clinical therapeutic window.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental exposure often high</td>
<td>Concentrated-extract genotoxicity is a potential safety limitation</td>
<td>G</td>
<td>Translation uncertain</td>
<td>Human tumor exposure, pharmacokinetics, standardized composition, dose-response relationships and oncology trial efficacy are not established. Culinary marjoram, tea, extracts and essential oil should not be considered equivalent formulations.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<hr>
<br>
<p><b>Alzheimer’s disease relevance:</b> Marjoram has meaningful but entirely preclinical AD-related evidence. In an intracerebroventricular Aβ1-42 rat model, inhaled Origanum majorana essential oil for 21 days improved memory performance, increased antioxidant activity and increased BDNF expression. A separate murine neuroinflammation model found hydroalcoholic marjoram extract reduced GFAP-associated astrogliosis and COX-2-associated neuroinflammation while improving recognition and spatial memory. Marjoram essential oil and isolated ursolic acid also inhibit acetylcholinesterase, and ursolic acid isolated from marjoram protects neuronal cells against Aβ-induced ROS and oxidative injury. More recent zebrafish data also support AChE inhibition, reduced oxidative stress and improved memory. These findings justify an AD mechanistic entry, but there is currently no evidence that marjoram prevents or treats Alzheimer’s disease in humans.</p>
<p><b>Primary AD mechanisms (ranked):</b></p>
<ol>
<li>Oxidative-stress suppression and neuronal protection against Aβ-associated oxidative injury.</li>
<li>Acetylcholinesterase inhibition, potentially increasing cholinergic signaling.</li>
<li>BDNF upregulation and support of memory-related neuroplasticity.</li>
<li>Suppression of neuroinflammation, reactive astrogliosis and COX-2 signaling.</li>
<li>Protection against Aβ1-42-associated cognitive dysfunction in animal models.</li>
</ol>
<p><b>Clinical evidence status:</b> Preclinical only for Alzheimer’s disease. Human neurological exposure data exist from small Parkinson’s disease trials, but these cannot be extrapolated to AD efficacy.</p>
<h3>Alzheimer’s disease mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oxidative stress and ROS</td>
<td>ROS ↓; lipid peroxidation ↓; antioxidant activity ↑</td>
<td>Neuronal oxidative injury ↓</td>
<td>Supported by Aβ-related cellular studies, Aβ1-42 rat studies and more recent cognitive models.</td>
</tr>
<tr>
<td>2</td>
<td>Acetylcholinesterase</td>
<td>AChE ↓</td>
<td>Acetylcholine degradation ↓</td>
<td>Observed with marjoram essential oil and strongly with isolated ursolic acid from O. majorana. Whole-herb potency and human brain exposure remain uncertain.</td>
</tr>
<tr>
<td>3</td>
<td>BDNF neuroplasticity</td>
<td>BDNF ↑</td>
<td>Memory and neuronal plasticity support ↑</td>
<td>Observed in the Aβ1-42 rat model following essential-oil inhalation.</td>
</tr>
<tr>
<td>4</td>
<td>Neuroinflammation</td>
<td>COX-2 ↓; inflammatory signaling ↓</td>
<td>Neuroinflammation ↓</td>
<td>Supported by LPS-induced murine neuroinflammation experiments.</td>
</tr>
<tr>
<td>5</td>
<td>Astrogliosis</td>
<td>GFAP ↓</td>
<td>Reactive astrocytosis ↓</td>
<td>Reduced GFAP immunoreactivity was observed in a murine neuroinflammation model.</td>
</tr>
<tr>
<td>6</td>
<td>Amyloid beta toxicity</td>
<td>Aβ-induced toxicity ↓</td>
<td>Neuronal survival ↑</td>
<td>Evidence includes isolated marjoram-derived ursolic acid and an Aβ1-42 animal model; evidence for direct reduction of amyloid production or plaque burden is insufficient.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Human AD evidence absent</td>
<td>Clinical efficacy unknown</td>
<td>Animal inhalation and extract doses cannot be directly converted into effective human AD dosing. CNS pharmacokinetics of standardized marjoram preparations remain poorly characterized.</td>
</tr>
</tbody>
</table>